Jeet Mukherjee
Stock Analyst at BTIG
(4.54)
# 271
Out of 5,111 analysts
16
Total ratings
68.75%
Success rate
29.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Buy | $27 → $30 | $19.01 | +57.81% | 4 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $75 → $138 | $85.68 | +61.06% | 3 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $167 | $88.98 | +87.68% | 1 | Dec 5, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $26 | $14.47 | +79.68% | 1 | Nov 7, 2025 | |
| ARVN Arvinas | Maintains: Buy | $10 → $14 | $12.34 | +13.45% | 2 | Oct 30, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $2.54 | +451.18% | 2 | Oct 13, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $87 → $104 | $75.12 | +38.45% | 3 | Sep 25, 2025 |
Nurix Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $19.01
Upside: +57.81%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $75 → $138
Current: $85.68
Upside: +61.06%
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $167
Current: $88.98
Upside: +87.68%
Aardvark Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $26
Current: $14.47
Upside: +79.68%
Arvinas
Oct 30, 2025
Maintains: Buy
Price Target: $10 → $14
Current: $12.34
Upside: +13.45%
Perspective Therapeutics
Oct 13, 2025
Reiterates: Buy
Price Target: $14
Current: $2.54
Upside: +451.18%
Monopar Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $87 → $104
Current: $75.12
Upside: +38.45%